Antinuclear antibody (ANA) testing is used in the diagnostic evaluation of various autoimmune diseases, including connective tissue diseases such as systemic lupus erythematosus (SLE), Sjögren syndrome, and systemic sclerosis (SSc).

Initial testing for autoimmune connective tissue diseases (also referred to as systemic autoimmune rheumatic diseases, or SARDs) should include tests for C-reactive protein (CRP), ANAs, rheumatoid factor, and cyclic citrullinated peptide antibodies.

If ANA results are positive, follow-up or confirmatory testing may be guided by the pattern(s) observed and/or the patient’s clinical presentation.

ANA by IFA (indirect immunofluorescence assay) with reflex to titer and pattern is a first-line screening test used to evaluate suspected autoimmune and connective tissue diseases. It detects antinuclear antibodies (ANA), which are immune proteins that can mistakenly target structures inside the nucleus of your own cells. If the ANA screen is positive, the lab automatically reports the antibody “titer” (how strong the result is) and the staining “pattern” (the fluorescence appearance), which can help clinicians decide which follow-up antibody tests are most appropriate and how likely an autoimmune condition may be based on symptoms and clinical history.

An ANA test detects antinuclear antibodies (ANA) in your blood. Your immune system normally makes antibodies to help you fight infection. In contrast, antinuclear antibodies often attack your body's own tissues — specifically targeting each cell's nucleus.

ANA IFA is a first line screen for detecting the presence of up to approximately 150 autoantibodies in various autoimmune diseases. A positive ANA IFA result is suggestive of autoimmune disease and reflexes to titer and pattern. Further laboratory testing may be considered if clinically indicated.

Usually, the results of the ANA test are reported in titers and patterns. The titer gives information about how many times the lab technician diluted the blood plasma to get a sample of ANAs.

The pattern of the ANA test can give information about the type of autoimmune disease present and the appropriate treatment program

Usually, the results of the ANA test are reported in titers and patterns. The titer gives information about how many times the lab technician diluted the blood plasma to get a sample of ANAs.

The pattern of the ANA test can give information about the type of autoimmune disease present and the appropriate treatment program

ANA IFA is a first line screen for detecting the presence of up to approximately 150 autoantibodies in various autoimmune diseases. A positive ANA IFA result is suggestive of autoimmune disease and reflexes to titer and pattern. Further laboratory testing may be considered if clinically indicated.

Antinuclear antibodies (ANA) are auto-antibodies against nuclear components, including double and single stranded DNA and histones. These antibodies can be detected with an ANA test. In this technique, a fluorescent-labeled immunoglobulin is used to detect immunoglobulin in the patient's serum against nuclear components. 

ANA IFA is a first line screen for detecting the presence of up to approximately 150 autoantibodies in various autoimmune diseases. A positive ANA IFA result is suggestive of autoimmune disease and reflexes to titer and pattern. Further laboratory testing may be considered if clinically indicated.

Antinuclear antibodies (ANA) are auto-antibodies against nuclear components, including double and single stranded DNA and histones. These antibodies can be detected with an ANA test. In this technique, a fluorescent-labeled immunoglobulin is used to detect immunoglobulin in the patient's serum against nuclear components. 

ANA IFA is a first line screen for detecting the presence of up to approximately 150 autoantibodies in various autoimmune diseases. A positive ANA IFA result is suggestive of autoimmune disease and reflexes to titer and pattern. Further laboratory testing may be considered if clinically indicated.

The ANA Screen, IFA is a gold-standard test used to detect antinuclear antibodies—immune proteins often present in autoimmune diseases such as lupus, Sjögren’s syndrome, and systemic sclerosis. This highly sensitive immunofluorescence method can identify up to approximately 150 different autoantibodies, making it an important first step in evaluating unexplained symptoms like joint pain, fatigue, rashes, or muscle weakness. A positive or negative ANA result helps guide your provider toward the next steps in diagnosis.

The ANA (antinuclear antibody) test screens for autoimmune disease. It's done by diluting your blood in steps and finding the highest dilution at which antibodies are still detectable — that dilution is your titer (e.g. 1:160). A staining pattern (homogeneous, speckled, nucleolar, centromere) is reported alongside it.

ANA is a sensitive but non-specific screen. Almost everyone with lupus is ANA-positive, but so are many healthy people — roughly a quarter to a third of healthy adults are positive at 1:40, and around 1 in 10 at 1:80. Positivity becomes more meaningful as the titer rises: 1:160 and 1:320 carry progressively higher suspicion, especially with symptoms like joint pain, rashes, fatigue, or dry eyes and mouth. A positive ANA on its own is not a diagnosis — it triggers more specific follow-up tests (anti-dsDNA, anti-Sm, anti-SSA/SSB, and others). Titer height does not reliably track how active or severe a disease is.

This anabolic/catabolic balance – or the balance of ‘growth and healing’ versus ‘wear and tear’ in the body – can be assessed by comparing total 17-hydroxycorticosteroids with total 17-ketosteroids in the urine.

The Anabolic/Catabolic Balance refers to the balance between "growth and healing" (anabolic) and "wear and tear" (catabolic) activity in the body. Both anabolic and catabolic metabolism are essential to health.

The Anabolic/Catabolic Balance refers to the balance between "growth and healing" (anabolic) and "wear and tear" (catabolic) activity in the body. Both anabolic and catabolic metabolism are essential to health.

The Anabolic/Catabolic Ratio is a critical marker that offers insight into the overall balance between anabolic (building and repairing) and catabolic (breaking down) metabolic processes in the body. This ratio is determined by comparing the levels of specific hormones and metabolites that are indicative of anabolism, such as DHEA (Dehydroepiandrosterone) and growth hormone metabolites, against those indicative of catabolism, like cortisol and its metabolites. An optimal balance between anabolic and catabolic processes is crucial for maintaining health, as it influences muscle strength, bone density, recovery from exercise, and overall energy levels.

An imbalance in this ratio, skewed towards catabolism, can signify a state of increased breakdown, often associated with stress, overtraining, poor nutrition, or illness. This state can lead to symptoms such as fatigue, muscle weakness, slow recovery from exercise, and poor general health. On the other hand, a shift towards anabolism, although necessary for growth and repair, when excessive, can indicate conditions like insulin resistance or abnormal growth hormone levels.

The ANAchoice Screen is a diagnostic test The ANAchoice Screen is a diagnostic test used to detect the presence of antinuclear antibodies (ANA) in the blood. ANAs are a group of antibodies that bind to certain contents of the nucleus of the cell and are often found in patients with certain autoimmune diseases, such as systemic lupus erythematosus (SLE), Sjögren's syndrome, and rheumatoid arthritis, among others. (ANA) in the blood. ANAs are a group of antibodies that bind to certain contents of the nucleus of the cell and are often found in patients with certain autoimmune diseases, such as systemic lupus erythematosus (SLE), Sjögren's syndrome, and rheumatoid arthritis, among others.

Anaerotruncus colihomonis (pronounced “an-AERO-trunk-us colly-HOM-in-iss”) is a newly described bacterial genus and species isolated from the stool specimens of children. Its clinical significance, however, is unknown.

The species is found only relatively infrequently in the human gut. It comes from the genus Anaerotruncus, which contains just this one species. The genus name comes from the Greek words “an” and “aero”, meaning respectively “without” and “air”, and the Latin word “truncus”, which means “stick”—making the overall name “a stick that lives without air”, since the cells of this bacterial genus are rod-like in shape and live in the absence of oxygen. The species name “colihominis” means “of the gut of man”.

The genus Anaerotruncus includes species Anaerotruncus colihominis and Anaerotruncus massiliensis.

A. colihominis hominis is a butyrate and acetate producer.

Abundance is associated with higher bacterial gene richness in the gut a.

A. colihominis is increased in healthy individuals and presumed to be anti-inflammatory.

There is an inverse correlation with high BMI and elevated serum triglycerides in older Amish adults.

There is an inverse relationship with A. colihominis abundance and cognitive function scores in patients with Alzheimer's disease.

Anaerotruncus massiliensis is a newly identified strain similar to A. colihominis. They both ferment amino acids and carbohydrates and are mucin degraders.